Purple Biotech Ltd. Sponsored ADR PPBT

1.49 0.01 0.68% as of 25 Sep

Follow PPBT

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio	—	—	—	—	+8 more quarters Free account
EV/Sales	—	—	—	—
EV/FCF	—	—	—	—
Quick Ratio	3.42	1.40	1.23	1.73
Current Ratio	3.70	1.48	1.27	1.78
Net Debt/EBITDA	4.97	2.94	0.41	7.99
Debt/Assets	0.00%	0.00%	0.00%	0.00%
Debt/Equity	0.00	0.00	0.00	0.00
Asset Turnover	0.00	0.00	0.00	0.00
Operating CF/Net income	(5.68)	36.29	0.05	0.82
Capex/Depreciation	(0.04)	0.00	(0.17)	0.14
Interest Coverage	0.00	0.00	0.00	0.00
Research and Development Expense of Revenue	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue	0.00%	0.00%	0.00%	0.00%
Intangible Assets out of Total Assets	0.52	0.51	0.42	0.71
Share Based Compensation of Revenue	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Yield	—	—	—	—
Revenue per Share	0.00	0.00	0.00	0.00
Operating CF per Share	(2.30)	(3.35)	(2.22)	(2.34)
Capex per Share	0.00	0.00	(0.02)	0.02
Free Cash Flow per Share	(2.31)	(3.35)	(2.24)	(2.32)
Cash per Share	5.62	6.90	19.94	22.95
Shareholders Equity per Share	11.25	10.38	20.12	72.04
Interest Debt per Share	0.00	0.00	0.00	0.00
Book value per Share	11.25	10.38	20.12	72.04
Free Cash Flow	(2.51)	(3.12)	(1.08)	(1.06)
Working Capital	4.81	2.19	2.11	4.72
Capital Expenditures	0.00	—	(0.01)	0.01
Net Current Asset Value	4.64	2.03	1.95	4.53
EV/EBIT	—	—	—	—
Capex to Sales	0.00	—	0.00	0.00
Net Profit Margin	0.00%	0.00%	0.00%	0.00%
Other line items
Average Payables	0.58	0.86	1.76	1.26
Average Assets	24.27	25.01	27.31	37.08
Average Common Equity	22.13	21.18	21.29	31.14

Columns are period end dates

Powerpack